Holistic Detoxification and Medical Care Needed to cure Opioid Addiction

Medical Care: Acute opioid-related disorders that require medical management include opioid intoxication, opioid overdose, and opioid withdrawal. Issues pertaining to treatment of chronic opioid abuse include opioid agonist therapy (OAT), psychotherapy, and treatment of acute pain in patients already on maintenance therapy.

Opioid intoxication and/or overdose

General supportive measures for opioid intoxication are as follows:
Assess patient to clear airway.
1. Provide support ventilation, if it is needed.
2. Assess and support cardiac function.
3. Provide IV fluids.
4. Frequently monitor the vital signs and cardiopulmonary status until the patient has cleared opioids from the system
5. Give IV naloxone if necessary. Naloxone is a specific opiate antagonist with no agonist or euphoriant properties. When administered intravenously or subcutaneously, it rapidly reverses the respiratory depression and sedation caused by heroin intoxication.

Opioid overdose

Naloxone is very effective in treating acute overdose, and is first-line treatment.


Because overdoses usually occur in the presence of other people and because medical care is often not sought or is sought too late, at-home naloxone programs have been piloted in several countries. This is a controversial treatment that raises concerns about condoning heroin use, discouraging medical care, and producing side effects that cannot be managed at home. However, the efficacy of these pilot programs should be carefully monitored, as the potential for reducing mortality is high.
Opioid agonist therapy (OAT): Pharmacologic therapy for heroin addiction has focused on ameliorating withdrawal symptoms and reducing cravings. By replacing heroin with legally obtained opioid agonists, many risk factors of the drug-abusing lifestyle can be mitigated.
Methadone maintenance therapy (MMT) has been the standard of care for more than 30 years. However, the recent advent of buprenorphine maintenance therapy (BMT) is changing the landscape of treatment for opioid-dependent patients.
Methadone
Methadone, a long-acting synthetic opioid agonist, can be dosed once daily and replaces the necessity for multiple daily heroin doses. As such, it stabilizes the drug-abusing lifestyle, reducing criminal behaviors, and also reducing needle sharing and promiscuous behaviors leading to transmission of HIV and other diseases.
However, methadone is a highly regulated Schedule II medication, only available at specialized methadone maintenance clinics. It is estimated that established methadone clinics can accommodate only 15-20% of US heroin addicts.
Methadone clinics often generate controversy in communities fearful of addicts in various stages of recovery. In addition, some patients are unable to travel to clinics, and others will not enter MMT because of fear of stigmatization. Clearly other options would be beneficial for treatment of chronic opioid abuse.
Buprenorphine
Buprenorphine is a mu-opioid partial agonist that, like methadone, suppresses withdrawal and cravings. However, the property of partial agonism confers a "ceiling effect," at which higher doses of buprenorphine cause no additional effects. This ceiling effect affords a wider margin of safety than methadone, which can be lethal in overdose. The increased safety of buprenorphine has allowed it to become available by prescription as a Schedule III medication.
Buprenorphine has been combined with naloxone in a 4:1 ratio (Suboxone) in order to alleviate concerns that the sublingual tablet would be dissolved and injected by addicts. Naloxone is an opioid antagonist that is poorly absorbed sublingually and orally but is well-absorbed intravenously. As a result, an opioid-dependent patient injecting buprenorphine/naloxone will suffer a withdrawal syndrome secondary to naloxone's occupation of mu-opioid receptors.
Office-based treatment of opioid addiction is now possible with BMT. Physicians wishing to prescribe buprenorphine must meet several criteria, including requirements outlined in the Drug Abuse Treatment Act of 2000. However, physicians who do not meet these criteria can take an 8-hour training course to become certified to prescribe buprenorphine. Currently, physicians are limited to 30 buprenorphine patients, but this restriction may soon be lifted.
LAAM: Historically, l-alpha-acetylmethadol (LAAM) has also been used for opioid-dependence maintenance pharmacotherapy. However, LAAM is associated with prolonged QT interval, and several cases of cardiac arrhythmia and death have been reported. Therefore, LAAM was recently removed from the market in the European Union and was given a black box label by the FDA.
Cochrane reviews: Several Cochrane Database Systematic Reviews about the efficacy of OAT have been published in recent years. While all of these reviews stress the need for larger, multicenter, randomized clinical trials of longer duration, some conclusions can be drawn from existing data.
A review of Cochrane reviews found that high-dose MMT (60-109 mg/d) is more effective in retaining patients in treatment than low-dose MMT (1-59 mg/d). Moreover, methadone at flexible doses was more effective in retaining patients in treatment (RR, 1.23) than buprenorphine. A second systematic review of databases found that low-dose methadone (20 mg/d) was less effective than buprenorphine (2-8 mg/d) and that high-dose methadone (>50-65 mg/d) was more effective than buprenorphine (2-8 mg/d).
Another Cochrane review found that oral substitution treatment was associated with significant reductions in heroin injection and needle sharing, as well as a decrease in patients with multiple sexual partners and a reduction in exchanges of sex for drugs or money. Importantly, these changes were correlated with reductions in cases of HIV infection.
A recent randomized, placebo-controlled trial suggested that an injectable, sustained-release form of naltrexone (Depotrex) increased retention of patients in treatment for opioid abuse. Further studies are necessary to evaluate the efficacy of this treatment modality.

Opiate withdrawal
Opiate withdrawal generally is considered less likely to produce severe morbidity or mortality compared with barbiturates and benzodiazepines. Safe withdrawal from opioids is termed detoxification and can be performed as outpatient or inpatient therapy, depending upon the following: presence of comorbid medical and psychiatric problems, availability of social support, and polydrug abuse.
Methadone, buprenorphine, and alpha-2 agonists, such as clonidine and lofexidine, are commonly used pharmacologic methods of detoxification. The use of methadone and buprenorphine is based on the principle of cross-tolerance in which one opioid is replaced with another and then slowly withdrawn. Alpha-2 agonists appear to be most effective in suppressing autonomically mediated signs and symptoms of abstinence, but they are less effective for subjective symptoms.
Two recent Cochrane reviews compared the efficacy of alpha-2 adrenergic agonists to methadone or buprenorphine for management of withdrawal. Patients experienced decreased side effects and stayed in treatment longer using tapered methadone compared to the alpha-2 agonists clonidine or lofexidine.
Buprenorphine was associated with fewer adverse effects than clonidine, and patients were more likely to complete withdrawal with buprenorphine compared with clonidine. Moreover, a second multicenter randomized trial demonstrated that buprenorphine-naloxone was more effective than clonidine for opioid detoxification.
Buprenorphine was equally effective as methadone for withdrawal completion, but withdrawal symptoms appeared to resolve more quickly with buprenorphine.
In summary, data, to date, suggest that buprenorphine and methadone are more effective than alpha-2 agonists, such as clonidine, for opioid detoxification, with buprenorphine associated with a shorter duration of withdrawal symptoms. However, all of these medications are effective, and the choice may depend in part on availability.

Psychotherapies and support groups: Detoxification alone, without ongoing treatment, is not adequate to manage patients.

Patients in methadone programs often benefit from cognitive behavioral, supportive, or analytical-oriented psychotherapies if they are added to standard drug counseling.
Cognitive behavior psychotherapy primarily focuses on the patient's thoughts and behaviors. Cognitive behavior–based models are widely used in drug rehabilitation programs. Cognitive behavior theories were aimed at substance abuse beginning in the mid 1980s. The techniques used help patients acquire specific skills for resisting substance use and teach coping skills to reduce problems related to drug use. Two major cognitive behavior theories of substance abuse are the following:
Relapse prevention: Based on the work of Marlatt and Gordon, important relapse prevention concepts and techniques include identification and avoidance of high-risk situations, understanding the chain of decisions leading to drug use, and changing one's lifestyle.
Cognitive therapy of substance abuse: Developed by Beck and colleagues, cognitive therapy of substance abuse is based on the concept that drug abusers engage in complex behaviors and thought processes, such as positive and negative drug-related beliefs and spontaneous flashes related to drug use before giving in to the actual drug use.
Dynamic psychotherapy is based on the concept that all symptoms arise from underlying unconscious psychological conflicts. The major goal of this therapy is to help the patient become aware of these conflicts and develop more adaptive coping mechanisms and healthier methods of resolving intrapsychic conflict.

Group therapy is argued to be especially effective because it can target the social stigma attached to having lost control of a substance. The presence of other group members who acknowledge having similar problems can provide support and be therapeutic in developing alternative methods of maintaining abstinence.

Aversion therapy involves pairing aversive stimuli to cognitive images of opioid use and conversely conjuring images of socially appropriate behaviors such as employment, education, and nondrug behavior.

Narcotics Anonymous (NA): In 1947, NA was formed in Lexington, Ky. NA is based on principles similar to those of Alcoholics Anonymous (AA), including progression through 12 steps of recovery. Some patients have difficulty engaging in the AA-NA approach to recovery; however, these programs do help some people and can provide much needed support for those attempting abstinence.
Acute pain management for patients receiving OAT: As more patients with opioid addiction receive OAT, physicians will encounter OAT patients with acute pain syndromes. It is important that acute pain be adequately treated in these patients.

Common misconceptions
OAT provides analgesia: Maintenance methadone or buprenorphine does not provide sustained analgesia. Although methadone and buprenorphine are potent analgesics, the analgesic properties last only 4-8 hours, while the medications are dosed every 24-48 hours.
Use of opioid analgesia may cause addiction relapse: No evidence indicates that exposure to opioid analgesics during acute pain increases relapse rates. In fact, evidence suggests that the stress of unrelieved pain can trigger relapse.
The combination of OAT and other opioids may cause respiratory depression: This is a theoretical risk that is not supported by clinical or empirical experience. Tolerance to respiratory and CNS depressant effects occurs rapidly and reliably.

Recommendations
Reassure patients that their addiction histories will not prevent adequate pain management, and discuss plans in a nonjudgmental manner.
Verify methadone and buprenorphine doses with clinics or prescribing physicians, and inform these physicians of any benzodiazepines or opioids given that may be detected on urine drug screening.
Aggressively treat pain with conventional opioid analgesics. Opioid cross-tolerance often necessitates higher opioid analgesic doses at shorter intervals.
Use continuous scheduled dosing orders rather than as-needed orders.
For patients receiving methadone maintenance therapy: Continue methadone maintenance dose and add short-acting opioid analgesics.
For patients receiving buprenorphine maintenance therapy: Pain management with opioids is complicated by the high affinity of buprenorphine for the mu receptor. This affinity may cause buprenorphine to compete with opioid analgesics at mu receptors. As buprenorphine's rate of dissociation from mu receptors is highly variable, naloxone should be available, and consciousness and respiration should be closely monitored.
Several options are possible, and the most effective approach will be determined with increasing clinical experience:
Continue BMT and titrate a short-acting opioid analgesic to effect.
Divide buprenorphine dose to 6-8 hours to take advantage of its short-acting analgesic properties.
Discontinue BMT, implement opioid analgesia, and restart BMT when opioid analgesia is no longer necessary.
In the hospitalized patient, discontinue BMT, initiate MMT, and add short-acting opioids to treat pain. Have naloxone at bedside. Convert back to BMT prior to discharge from hospital.

• Bibliography
  
  Alford DP, Compton P, Samet JH: Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006 Jan 17; 144(2): 127-34
• Amato L, Davoli M, A Perucci C, et al: An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005 Jun; 28(4): 321-9
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington DC: American Psychiatric Association; 2000.
• Cicero TJ, Inciardi JA, Munoz A: Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005 Oct; 6(10): 662-72
• Comer SD, Sullivan MA, Yu E, et al: Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006 Feb; 63(2): 210-8
• Dertwinkel R, Wiebalck A, Zenz M: [Oral opioids for long-term treatment of chronic non-cancer pain]. Anaesthesist 1996 Jun; 45(6): 495-505 [Medlin
• Dobson KS: Historical and Philosophical bases of the cognitive-behavioral therapies. Handbook of Cognitive-Behavioral Therapies. 1998; 3-38.
• Fischer B, Rehm J, Kim G, Kirst M: Eyes wide shut?--A conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res 2005; 11(1): 1-9; discussion 10-4 [Medline]
• Gardner EL: Brain Reward Mechanisms. Substance Abuse- A Comprehensive Textbook. 1997; 51-70.
• Gowing L, Farrell M, Bornemann R: Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2004; Medline]
• Gowing L, Ali R, White J: Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2004;
• Gowing L, Farrell M, Ali R: Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2004;
• Herz A: Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol 1998 Mar; 76(3): 252-8
• Jaffe JH: Opioid related disorders. Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry. 6th ed. 1995.
• Jaffe JH, Jaffe AB: Opioid-related disorders. In: Comprehensive Textbook of Psychiatry. Vol 1 . 2000: 1038-63.
• Kleber HD, Gold MS, Riordan CE: The use of clonidine in detoxification from opiates. Bull Narc 1980; 32(2): 1-10 [Medline]
• Kouyanou K, Pither CE, Wessely S: Medication misuse, abuse and dependence in chronic pain patients. J Psychosom Res 1997 Nov; 43(5): 497-504.
• Li L, Smialek JE: Observations on Drug Abuse Deaths in The State of Maryland. J Forensic Sci 1996; 41: 106-9.
• Ling W, Amass L, Shoptaw S, et al: A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005 Aug; 100(8): 1090-100.
• Marsch LA, Bickel WK, Badger GJ, et al: Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 2005 Oct; 62(10): 1157-64.
• McCance-Katz EF: Office-based buprenorphine treatment for opioid-dependent patients. Harv Rev Psychiatry 2004 Nov-Dec; 12(6): 321-38.
• Moskalewicz J, Sieroslawski J: [Mortality of narcotic addicts using injections]. Przegl Epidemiol 1996; 50(3): 323-32.
• Rounsaville BJ, Galanter M, Frawley PJ: Behavioral Therapies for Addiction. Principles of Addiction Medicine. 1998: 595-690.
• Saxon AJ, Oreskovich MR, Brkanac Z: Genetic determinants of addiction to opioids and cocaine. Harv Rev Psychiatry 2005 Jul-Aug; 13(4): 218-32.
• Simoens S, Matheson C, Bond C, et al: The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract 2005 Feb; 55(511): 139-46.
• Smith MO, Khan I: An acupuncture programme for the treatment of drug-addicted persons. Bull Narc 1988; 40(1): 35-41.
• Sporer KA: Strategies for preventing heroin overdose. British Medical Journal 2003; 326: 442-444.
• Stine S, Meandzija B, Kosten R: Pharmacologic Therapies for Opioid Addiction. Principles of Addiction Medicine. 1998: 545-555.